摘要
Abstract
Objective To assess the response rates ( clinical and pathological ) with docetaxel and epirubicin combination chem-otherapy and its effect on outcome .Methods Locally advanced breast cancer ( LABC) patients who received NACT from January 2009 to December 2012 in this hospital were retrospectively analysed .Some information of the patients was collected including basic informa-tion, clinical stages and the situation of estrogen receptor and progesterone receptor .The regimens used for NACT consisted of six cycles of DEC (docetaxel 75 mg/m2, epirubicin 75 mg/m2, cyclophosphamide 500 mg/m2 on day 1, 3 weekly) and a sequential regimen (4 cy-cles of FEC, 5-flurouracil 600 mg/m2 , epirubicin 75 mg/m2 , cyclophosphamide 600 mg/m2 followed by 4 cycles of docetaxel 85 mg/m2 ) .Clinical response and pathological response rates , time of relapse and 3 year survival rate were assessed .Results The median age was 46 years.Ninety-six patrents (80%) had T4 disease and 90%had clinically palpable lymph nodes at diagnosis .The median size of primary tumor at presentation was 5.9 cm.Hormone receptor positivity was seen in 55%of patients and HER2/neu positivity in 25%. Triple negative breast cancers constituted of 25%of the patients.Totally 100 cases showed clinical response , accounting for 83%;15 ca-ses showed clinical stability;5 cased showed clinical progress .18 cases showed pathological response .There were no significant differ-ences between the two groups in the above data .The median duration of follow-up was 22 months.The median time to relapse was 20 months;3 year relapse free and overall survival rates were 50%and 70%, respectively .The differences between the two groups was not statically significant .Conclusions LABC patients have good outcome after neoadjuvant chemotherapy .Sequential chemotherapy is well tolerated than concurrent docetaxel and epirubicin chemotherapy with a similar PCR ( pathological complete response ) .关键词
乳腺癌/新辅助化疗/多西他赛/表柔比星/预后Key words
Breast cancer/neoadjuvant chemotherapy/docetaxel/epirubicin/outcome分类
医药卫生
